Financial Performance - Total revenue for the year ended December 31, 2024, reached RMB 17,903,608, representing a 5.5% increase from RMB 16,972,276 in 2023[5]. - Adjusted net profit for the year was RMB 156,734, a 20.1% increase compared to RMB 130,542 in the previous year[5]. - Gross profit for the year was RMB 1,813,451, reflecting a 4.2% increase from RMB 1,740,923 in 2023[5]. - The net profit for the year ended December 31, 2024, was RMB 15.1 million, a significant recovery from a loss of RMB 3,206.5 million for the year ended December 31, 2023, marking the first profitable year for the company[82]. - The adjusted net profit margin for the year ended December 31, 2024, was 0.9%, compared to 0.8% for the year ended December 31, 2023[88]. - The company's sales cost rose by 5.6% to RMB 16,090.2 million for the year ending December 31, 2024, compared to RMB 15,231.4 million for the year ending December 31, 2023, mainly due to increased sales in the self-operated business[70]. - The gross margin for the self-operated business improved from 6.1% to 6.2% due to a higher proportion of exclusive strategic partnerships and proprietary brands in the product line[73]. - The company reported a significant decrease in other business revenue, dropping 21.1% to RMB 49.6 million for the year ending December 31, 2024, from RMB 62.9 million for the year ending December 31, 2023, due to adjustments in the operational/service model of spectral cloud testing[69]. User Engagement and Market Reach - The number of downstream users served exceeded 820,000, providing comprehensive digital solutions[8]. - As of December 31, 2024, the cumulative registered buyers exceeded 827,000, including 491,000 pharmacies and 330,000 primary medical institutions[23]. - The average monthly active buyers reached 433,000, representing an 18.0% year-over-year growth, while the average monthly paying buyers were 401,000, up 17.2% year-over-year[23]. - The average order number per paying buyer was approximately 28.5 orders per month[23]. - The platform's average SKU count increased to over 3,900,000, fulfilling diverse customer needs[26]. Product and Service Development - The platform's non-pharmaceutical product SKU count increased by approximately 50% during the reporting period[11]. - The company successfully onboarded around 600 traditional Chinese medicine manufacturers, enhancing product quality from the supply chain[11]. - The exclusive strategic partnership and proprietary brand products saw SKU growth of approximately 700, with transaction scale increasing by about 220% year-on-year[13]. - The company is focusing on the POCT auxiliary diagnosis market, launching various instant testing devices tailored for primary healthcare institutions[16]. - The company has launched a logistics platform to monitor the entire process of vehicle loading, transportation, and delivery, improving service efficiency[32]. Operational Efficiency - The company's order fulfillment efficiency improved, with same-day delivery orders increasing from 58.6% to 68.9% compared to the same period last year[12]. - The average warehouse processing time was completed within approximately 3 hours, with inter-provincial delivery taking about 38 hours to cities and 49 hours to towns[32]. - The unit fulfillment cost for self-operated same-city delivery decreased by 12.87%, while the proportion of orders delivered within half a day increased from 58.6% in 2023 to 68.9% in 2024[32]. - The return rate decreased from 0.5% in the previous year to 0.4% during the reporting period, reflecting strict quality control measures[34]. Strategic Initiatives - The company is advancing its digital transformation strategy, integrating AI and big data analytics to enhance system efficiency and user satisfaction[16]. - The company aims to strengthen its existing platform and proprietary business in the outpatient pharmaceutical industry, leveraging AI technology for service quality enhancement[19]. - The company is focusing on digital transformation and enhancing user experience through data-driven insights and service optimization[24]. - The company plans to enhance its supply chain capabilities and expand its spectrum cloud testing services[125]. Corporate Governance and Compliance - The board of directors is committed to achieving high standards of corporate governance to protect shareholder interests and enhance corporate value[109]. - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2024, and discussed accounting policies and internal controls with the management[115]. - The company has complied with the corporate governance code and has not deviated from the recommended practices, except for the dual role of the chairman and CEO[111]. Future Outlook - Looking ahead to 2025, the company aims to strengthen its existing platform and proprietary business in the outpatient pharmaceutical industry, leveraging AI technology for service quality enhancement[19]. - The company plans to optimize its product supply system and continuously expand its product categories, introducing more quality and innovative pharmaceutical products and health services[61]. - The company aims to actively promote investments and acquisitions in the industry chain to inject new momentum into long-term development and achieve strategic upgrades towards ecosystem and diversification[66].
药师帮(09885) - 2024 - 年度业绩